Holen Sie sich die Stockscreener-App
7.16
2.07%
0.145
Handel nachbörslich:
7.16
Schlusskurs vom Vortag:
$7.015
Offen:
$6.96
24-Stunden-Volumen:
1.48M
Relative Volume:
1.28
Marktkapitalisierung:
$525.05M
Einnahmen:
$11.40B
Nettoeinkommen (Verlust:
$-95.73M
KGV:
-3.598
EPS:
-1.99
Netto-Cashflow:
$-64.37M
1W Leistung:
+0.00%
1M Leistung:
-4.79%
6M Leistung:
-1.24%
1J Leistung:
+113.73%
1-Tages-Spanne:
$6.9225
$7.355
1-Wochen-Bereich:
$6.87
$8.115
52-Wochen-Spanne:
$3.37
$12.22
Mind Medicine Inc Stock (MNMD) Company Profile
Firmenname
Mind Medicine Inc
Sektor
Branche
Telefon
212-220-6633
Adresse
ONE WORLD TRADE CENTER, NEW YORK
Vergleichen Sie MNMD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MNMD
Mind Medicine Inc
|
7.16 | 525.05M | 11.40B | -95.73M | -64.37M | -2.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Mind Medicine Inc Stock (MNMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-14 | Fortgesetzt | Leerink Partners | Outperform |
| 2024-07-24 | Eingeleitet | ROTH MKM | Buy |
| 2024-05-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-04-15 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-12-09 | Fortgesetzt | ROTH Capital | Buy |
| 2022-11-16 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-26 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-05-04 | Eingeleitet | ROTH Capital | Buy |
| 2021-06-28 | Eingeleitet | Maxim Group | Buy |
Alle ansehen
Mind Medicine Inc Aktie (MNMD) Neueste Nachrichten
Chardan Capital Initiates Coverage of Mind Medicine (MNMD) with Buy Recommendation - MSN
Mind Medicine (MindMed) (NASDAQ:MNMD) Now Covered by Analysts at Chardan Capital - MarketBeat
Wellington Management Group LLP Purchases 109,152 Shares of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
MindMed joins Nasdaq Biotechnology Index - Investing.com
MindMed Joins Nasdaq Biotech Index After Landmark Year of $250M Funding and Clinical Advances - StockTitan
Objective long/short (MNMD) Report - Stock Traders Daily
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading 4.9% HigherStill a Buy? - MarketBeat
Mind Medicine (MindMed) (NASDAQ:MNMD) Receives "Outperform" Rating from Oppenheimer - MarketBeat
MindMed doses first subject in trial of tablets for generalised anxiety disorder - Yahoo Finance
MindMed Announces First Patient Dosed in Phase 3 Voyage Study of MM120 in Generalized Anxiety Disorder (GAD) - newsbreak.com
Brokerages Set Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Price Target at $27.71 - MarketBeat
Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment By Investing.com - Investing.com South Africa
Mind Medicine's SWOT analysis: stock poised for growth in anxiety treatment - Investing.com India
MindMed Scientific Presentations at American College of Neuropsychopharmacology (ACNP) 2024 Congress - Business Wire
MindMed Showcases Breakthrough LSD Treatment Data for Anxiety Disorder at Major Congress - StockTitan
Learn to Evaluate (MNMD) using the Charts - Stock Traders Daily
MindMed awarded Innovation Passport for MM120 - The Pharma Letter
Insider Buying: David Gryska Acquires Additional Shares of Mind Medicine Inc (MNMD) - GuruFocus.com
Mind Medicine director David Gryska acquires $17,925 in shares - Investing.com
Mind Medicine director David Gryska acquires $17,925 in shares By Investing.com - Investing.com Nigeria
MindMed gains UK Innovation Passport for GAD treatment - Investing.com
MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD) - Business Wire
MindMed Appoints Javier Muniz, M.D., as Vice President of Research and Development Strategy - citybiz
MindMed appoints new VP of R&D Strategy - Investing.com
MindMed appoints new VP of R&D Strategy By Investing.com - Investing.com UK
MindMed Announces New Employee Inducement Grants - Business Wire
MindMed Issues Stock Options to New Employees in Latest Inducement Grant - StockTitan
Mind Medicine (MindMed) (NASDAQ:MNMD) Trading Down 3%Time to Sell? - MarketBeat
Ally Bridge Group NY LLC Decreases Stock Holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) - MarketBeat
Mind Medicine (NEOE:MMED) Change In Inventory : C$0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
MindMed's SWOT analysis: psychedelic stock's potential in anxiety treatment - Investing.com
Roth Capital Issues Pessimistic Estimate for MNMD Earnings - MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) Receives $25.38 Average Price Target from Brokerages - MarketBeat
Generalized Anxiety Disorder Market to Reach New Heights - openPR
MindMed recruits regulatory expert ahead of Phase III trials - The Pharma Letter
Vera hires Jason Carter as chief legal officer - BioCentury
MindMed Appoints Gregg Pratt, Ph.D. as Chief Regulatory and Quality Assurance Officer - BioSpace
MindMed Appoints Former Karuna Executive to Lead Phase 3 Regulatory Strategy | MNMD Stock News - StockTitan
(MNMD) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Is Mind Medicine (MNMD) the Best Multibagger Stock to Buy Heading into 2025? - Insider Monkey
Mind Medicine (MindMed) (NASDAQ:MNMD) Shares Gap UpHere's What Happened - MarketBeat
Stock Traders Purchase Large Volume of Call Options on Mind Medicine (MindMed) (NASDAQ:MNMD) - MarketBeat
COMMODORE CAPITAL LP Acquires Shares in Mind Medicine Inc - GuruFocus.com
10 Best Multibagger Stocks To Buy Heading into 2025 - Insider Monkey
Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) market cap touched US$601m last week, benefiting both retail investors who own 41% as well as institutions - Yahoo Finance
Mind Medicine Mindmed Inc (MNMD-Q) QuotePress Release - The Globe and Mail
Can Canada’s psychedelic drug developers shake off the sector’s bad trip? - The Globe and Mail
MindMed to Participate in Upcoming Investor Conferences - Business Wire
Mind Medicine (MindMed)'s (MNMD) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Mind Medicine: No News = Good News (NASDAQ:MNMD) - Seeking Alpha
Adam Stanecki on Mind Medicine with Charles Kovess11 November 2023 - imdb
Finanzdaten der Mind Medicine Inc-Aktie (MNMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):